Key result
Heterologous NVX-CoV2373 booster elicits a ~7-fold rise in ancestral neutralizing antibodies but weaker Omicron responses.
Why the study?
The immunogenicity and short-term durability of NVX-CoV2373 as a heterologous COVID-19 booster in adults primed with different vaccines were not fully characterized.
Does a single booster dose of NVX-CoV2373 improve binding and pseudovirus-neutralizing antibody responses in adults primed with Ad26.COV2.S, mRNA-1273, or BNT162b2 vaccines?
Population
Adults primed with Ad26.COV2.S, mRNA-1273, or BNT162b2 vaccines
Comparison
Single heterologous booster dose of NVX-CoV2373
Design
Multicenter open-label study
Follow-up
Through Day 91
Authors
Loading...
Supports NVX-CoV2373 as a safe heterologous booster alternative; extends RCT evidence for protein subunit platforms after mRNA or adenoviral priming.
Does a single booster dose of NVX-CoV2373 improve binding and pseudovirus-neutralizing antibody responses in adults primed with Ad26.COV2.S, mRNA-1273, or BNT162b2 vaccines?
Heterologous boosting with the protein-based NVX-CoV2373 vaccine is immunogenic and safe, offering an acceptable alternative to mRNA or adenoviral-based boosters.
Lyke et al. (2023) studied COVID-19 Vaccination (n=67). NVX-CoV2373 was evaluated on Pseudovirus neutralizing antibody (PsVNA) geometric mean fold rise against D614G at Day 29. A single heterologous booster dose of NVX-CoV2373 was well-tolerated and elicited a 6.4- to 7.8-fold rise in neutralizing antibody titers against the ancestral D614G strain, with lower responses against Omicron sub-lineages.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: